2nd Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$802,333
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 19, 2016 $802,333 Replaced
2nd Quarter - Amendment Jul 21, 2017 $800,000 Yes

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Inter Partes Review (IPR) process.

LobbyistCovered position, as disclosed
MICHAEL BRZICA —
THOMAS JAMES GARRIGAN —
HEIDI WILSON —

Contacted: U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Trade (domestic/foreign) TRD

Trans-Pacific Partnership (TPP). Biologic Exclusivity.

LobbyistCovered position, as disclosed
MICHAEL BRZICA —
KATHRYN LEE ANDERSON CHADWICK New —
HEIDI WILSON —

Contacted: SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Taxation/Internal Revenue Code TAX

Taxation Issues Related to Opioid Pharmaceuticals. S.3075: Addiction Prevention and Responsible Opioid Practices Act. S.2977: Budgeting for Opioid Addiction Treatment Act.

LobbyistCovered position, as disclosed
MICHAEL BRZICA —
CHRISTIAN OMAR CRUZ —
HEIDI WILSON —

Contacted: Food & Drug Administration (FDA); U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 3075 (114th), S. 2977 (114th)

Health Issues HCR

Innovation for Healthier Americans Initiative. H.R.6: 21st Century Cures Act.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
CHRISTIAN OMAR CRUZ —
THOMAS JAMES GARRIGAN —
CHRISTINE SIMMON —
HEIDI WILSON —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6 (114th)

Medicare/Medicaid MMM

Medicare Part D Program and Generic Drugs. Medicare reimbursement for biosimilars. H.R.1314: Bipartisan Budget Act of 2015. Covered Outpatient Drugs (CMS-2345-FC). CMMI Part B Drug Demo.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
CHRISTIAN OMAR CRUZ —
THOMAS JAMES GARRIGAN —
CHRISTINE SIMMON —
HEIDI WILSON —

Contacted: Food & Drug Administration (FDA); SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1314 (114th)

Budget/Appropriations BUD

FDA Funding. S.2956: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. H.R.5054: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. H.R.1314: Bipartisan Budget Act of 2015. S.2837: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2017. S.3040: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.3020: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
CHRISTIAN OMAR CRUZ —
HEIDI WILSON —

Contacted: U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3040 (114th), H.R. 5054 (114th), S. 2837 (114th), S. 2956 (114th), H.R. 1314 (114th), H.R. 3020 (114th)

Pharmacy PHA

Implementation of Food and Drug Administration Safety and Innovation Act (FDASIA) and Generic Drug User Fee Amendments (GDUFA). Labeling of Generic Drugs. Biosimilars Naming. Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products. Prescription Drug Costs. H.R.2841: FAST Generics Act of 2015. H.R.1314: Bipartisan Budget Act of 2015. Drug Importation. Risk Evaluation and Mitigation Strategies (REMS). Biologic Exclusivity. Biologics Price Competition and Innovation Act (BPCIA). S.2615: Increasing Competition in Pharmaceuticals Act. Pharmaceutical exclusivity. H.R.4931: Pharmaceutical Stewardship Act of 2016. H.R.953: Comprehensive Addiction and Recovery Act of 2015 (CARA). S.3056: CREATES Act of 2016.

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); SENATE

Bills named: H.R. 4931 (114th), S. 3056 (114th), H.R. 1314 (114th), H.R. 2841 (114th), H.R. 953 (114th), S. 2615 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.